Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 2 2Phase 1 2

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Brain Neoplasms 3Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Oligodendroglioma 1Melanoma 1Lung Neoplasms 1Hematologic Neoplasms 1Glioma 1Glioblastoma 1Ependymoma 1Disease 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

Paclitaxel 81Trastuzumab 76Fulvestrant 55Cyclophosphamide 49Capecitabine 42Lapatinib 40pembrolizumab 39Docetaxel 38palbociclib 36Carboplatin 33Letrozole 28olaparib 23Doxorubicin 23Gemcitabine 21Taxes 20Everolimus 20ribociclib 19abemaciclib 19Ado-Trastuzumab Emtansine 18pertuzumab 17Radiotherapy 17Magnetic Resonance Spectroscopy 17Bevacizumab 16130-nm albumin-bound paclitaxel 16exemestane 15Vinorelbine 15Cisplatin 15veliparib 14Biopsy 14Alpelisib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Breast Neoplasms × alovudine × Clear all
NCT01251874 2026-05-22

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
44 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02608216 2025-09-03

[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer

University of Pennsylvania

Phase 1 Active not recruiting
20 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡